Related Experiment Videos
Thrombotic thrombocytopenic purpura
B Lämmle1, J A Kremer Hovinga, L Alberio
1Department of Hematology and Central Hematology Laboratory, Inselspital, University Hospital, Bern, Switzerland. bernhard.laemmle@insel.ch
Journal of Thrombosis and Haemostasis : JTH
|August 17, 2005
Summary
Thrombotic thrombocytopenic purpura (TTP) is a serious condition linked to ADAMTS13 deficiency. Early diagnosis and treatment, including plasma exchange and FFP infusions, are crucial for managing TTP and preventing relapses.
Area of Science:
- Hematology
- Genetics
- Pathophysiology
Background:
- Thrombotic thrombocytopenic purpura (TTP) has evolved from a fatal disease to a manageable condition with advancements in understanding its underlying mechanisms.
- The discovery of ADAMTS13 deficiency as a key factor in acute TTP marked a significant turning point in diagnosis and treatment.
Observation:
- ADAMTS13, a metalloprotease, regulates unusually large von Willebrand factor (VWF) multimers, and its deficiency is central to TTP pathogenesis.
- Both hereditary and acquired forms of TTP exist, with acquired TTP often linked to autoantibodies against ADAMTS13.
- Other thrombotic microangiopathies (TMAs), including hemolytic uremic syndrome (HUS), have distinct etiologies, such as infections or genetic abnormalities.
Findings:
- New assays for ADAMTS13 activity are being developed to improve diagnostic accuracy.
- Hereditary TTP results from ADAMTS13 gene mutations, necessitating early clinical recognition for effective treatment.
- Acquired TTP, particularly when associated with severe ADAMTS13 deficiency, carries a high risk of relapse, underscoring the need for ongoing management strategies.
Implications:
- Improved diagnostic tools and a deeper understanding of TMA pathophysiology are essential for tailoring patient management.
- Prompt treatment of TTP, utilizing plasma exchange and fresh frozen plasma (FFP), can reverse acute episodes and prevent fatal outcomes.
- Further research is needed to refine treatment strategies for various forms of TTP and related TMAs, aiming for improved patient outcomes and reduced relapse rates.